Dipna Pharmachem Ltd
Incorporated in 2011, Dipna Pharmachem Ltd
is in the business of Pharmaceutical Trading[1]
- Market Cap ₹ 50.7 Cr.
- Current Price ₹ 21.1
- High / Low ₹ 26.3 / 6.40
- Stock P/E 52.2
- Book Value ₹ 16.0
- Dividend Yield 0.00 %
- ROCE 6.64 %
- ROE 2.55 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Promoter holding is low: 9.98%
- Company has a low return on equity of 3.62% over last 3 years.
- Debtor days have increased from 103 to 135 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|
17 | 20 | 30 | 31 | 73 | 100 | 164 | 125 | |
16 | 20 | 30 | 31 | 71 | 98 | 161 | 121 | |
Operating Profit | 0 | 0 | 0 | 0 | 2 | 2 | 3 | 4 |
OPM % | 2% | 2% | 1% | 1% | 3% | 2% | 2% | 3% |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Interest | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 |
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit before tax | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 |
Tax % | 14% | 40% | 0% | 60% | 26% | 34% | 24% | 32% |
0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | |
EPS in Rs | 6.00 | 3.00 | 6.00 | 2.00 | 117.00 | 0.37 | 0.45 | 0.40 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 33% |
3 Years: | 20% |
TTM: | -24% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 74% |
3 Years: | -6% |
TTM: | -11% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 193% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 5% |
3 Years: | 4% |
Last Year: | 3% |
Balance Sheet
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|
Equity Capital | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 12 | 24 | 24 |
Reserves | 0 | 0 | 1 | 1 | 2 | 12 | 13 | 14 |
5 | 6 | 10 | 12 | 10 | 16 | 19 | 17 | |
6 | 8 | 8 | 12 | 24 | 37 | 76 | 77 | |
Total Liabilities | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 | |
Total Assets | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 |
Cash Flows
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|
-3 | -2 | 3 | -21 | -5 | -9 | |||
0 | 0 | -0 | -0 | -0 | -0 | |||
3 | 2 | -3 | 26 | 14 | -4 | |||
Net Cash Flow | 0 | 0 | -0 | 5 | 8 | -13 |
Ratios
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|
Debtor Days | 132 | 160 | 134 | 176 | 135 | 104 | 69 | 135 |
Inventory Days | 112 | 66 | 70 | 89 | 34 | 72 | 86 | 88 |
Days Payable | 142 | 148 | 105 | 145 | 123 | 139 | 172 | 243 |
Cash Conversion Cycle | 103 | 78 | 99 | 120 | 46 | 38 | -17 | -20 |
Working Capital Days | 3 | 6 | 44 | 47 | 37 | 108 | 80 | 137 |
ROCE % | 8% | 5% | 3% | 17% | 9% | 7% | 7% |
Documents
Announcements
- Intimation Of Book Closure Pursuant To Regulation 42 Of The SEBI (Listing Obligation And Disclosure Requirement) Regulation, 2015 8 Aug
-
Outcome Of Board Meeting & Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
8 Aug - Authorized capital increased to 25.5 Cr shares; FY24-25 report approved; AGM on 30 Aug 2025 via VC.
- Reg. 34 (1) Annual Report. 8 Aug
-
Notice Of Annual General Meeting To Be Held On 30Th August, 2025
8 Aug - Notice and annual report for 14th AGM on Aug 30, 2025; includes financials, director appointments, related party transactions up to Rs.100 Cr, and authorized capital …
-
Board Meeting Outcome for Outcome Of Board Meeting
8 Aug - Board approved Rs. 5 lakh share capital increase, FY24-25 report, and scheduled 14th AGM on 30 Aug 2025.
Business Overview:[1]
DPL is a trader, importer, and exporter of industrial Chemical and Pharmaceutical Raw materials, APIs, Solvents, Excipients, Intermediates, and Formulations. It provides assistance in setting up contract manufacturing compliance for regulated, semi-regulated pharmaceutical companies with all the global benchmark parameters of certificates like WHO-GMP